Iterum Therapeutics Plc (ITRM)

$0.03 -0.04 (-57.39%)
Market Cap 1.60M
Revenue (ttm) 0.00
Net Income (ttm) -24.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -2.88
Volume 65,735,500
Avg Vol 19,797,338
Day's Range N/A - N/A
Shares Out 53.29M
Stochastic %K 2%
Beta 2.96
Analysts Hold
Price Target $9.00

Company Profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 903 8354
Address:
3 Dublin Landings, North Wall Quay, Dublin, Ireland
Steloco1
Steloco1 Aug. 9 at 1:09 PM
$ITRM Given the facts how this ludicrous loan was written, I'm hoping the court will only allow the original principal 51m.plus interest for RLN payment, of course hoping for far less. But Sarissa wants payment so where's the medium? Seems that would be a win for all to settle the RLN ordeal for a clean title. Since there's no royalty's on US sales and can't claim CIC this may be a compormidable bargaining solution.
1 · Reply
Amb8675309
Amb8675309 Aug. 9 at 7:15 AM
$ITRM I see they’re 25,000 watchers on this stock and there’s probably seven of us that regularly do anything so let me set the record straight- because I’ve blocked this guy that had zero followers and was following no one. We made a huge investment in this stock. The CEO misled me personally and I’m willing to testify to that. He spoke to other retail investors as well. People lost hundreds of thousands of dollars- the reason he could not sell when he received lowball offers is because he’s the one that entered into a terrible loan with Sarissa. He had a fiduciary duty to us, but he basically doomed himself. He made his asset unsellable except via liquidation . And because of that, I know people on here that lost huge chunks of their retirement account- hundreds of thousand of dollars- so if you don’t have anything to say, don’t question me as a larger shareholder- take your opinion and block me - I don’t want to hear it.
2 · Reply
Amb8675309
Amb8675309 Aug. 9 at 1:33 AM
$ITRM dead man walking- so talking to Us like he was serious about a launch- not cool
1 · Reply
Amb8675309
Amb8675309 Aug. 8 at 7:26 PM
$ITRM so when did CF know he was going to end up liquidating? As I said months ago, CF was a “dead man walking” the minute he received that 2021 CRL. To do another phase 3 would take 2 more years plus monthly cash burn plus new ph.3 trial costs/fees. CF agreed to terrible loan terms and omitted a CRL clause in the RLN master docs because of hubris and inexperience. I’m sure he realized this mistake THE DAY he received that CRL. By the time he gets approved in late 2024, CF knows he can’t actually fund a full 3 year launch. So here come lowballs- they’re low bec CF has no cash+unproven GTM thesis: of first office visit script should be Orly if patient chart warrants it, PLUS those pesky RLN holders have right to demand max. 414Mil. CF doesn’t “waste time” his actual answer to me of WTF did he do between 2024 low balls and an Aug 20/25 launch. He goes to PFE for 3yr extension- and PFE says, “sure” but no more non dilutive financing unless we approve it. CF knows proxy votes will fail…
1 · Reply
Adamantia
Adamantia Aug. 8 at 2:41 PM
$ITRM CROOKS I HOPE FISHMAN ROT'S IN A PLACE WORSE THAN HELL ,IN A BASEMENT SCREWED TO A WALL AND SLOWLY TAKING HIM ..... I'LL LEAVE THE REST TO THE FAMILY HERE THAT LOST ALL THEIR MONEY..
1 · Reply
DollerADay
DollerADay Aug. 8 at 3:52 AM
$ITRM For Teneo, a zero-equity outcome now risks looking catastrophic. Shareholders lost normal financial visibility during Orlynvah’s critical commercial inflection, and liquidation arrived just two business days before Q1 ended. Yet the filing described two counterparties discussing acquisition terms and a company that ran out of time and cash—not a failed drug or worthless asset. Teneo then presided over 5+ months of silence while DTC disappeared, massive trading continued, brokers removed positions, and shareholder custody records fractured. If this ends with a substantial sale and zero for equity, Teneo will have created an extraordinarily hostile factual record around that result. Bidder communications, valuations, RLN treatment, Pfizer economics and the entire waterfall become obvious targets for scrutiny. The custody disaster makes it worse: shareholders can reasonably ask why Teneo remained silent while ownership records deteriorated if equity supposedly never mattered.
2 · Reply
DollerADay
DollerADay Aug. 8 at 3:37 AM
$ITRM You can scroll through the history where I explained your next steps to this broker/custodian issue. This isn’t a new corporate action. What everyone here should be doing is “like” and repost the Tweets about this very issue under $ITRM. For Teneo to remain in absolute silence for going on 5 months in this custody disaster is indicative of one thing and one thing only.
2 · Reply
Hung25_25
Hung25_25 Aug. 8 at 2:03 AM
$ITRM it's my trun
0 · Reply
DollerADay
DollerADay Aug. 7 at 8:17 PM
$ITRM Here are the biggest AMR events of the year: ESCMID Global in April was the biggest major ID/AMR meeting already missed. * GAMRIC in September is the best remaining specialist AMR-development audience. * IDWeek in October is the strongest remaining U.S. clinical/commercial stage. * WAAW in November is the strongest global public-policy stage. ESCMID Global 2026 made one message unmistakable: antimicrobial resistance is accelerating, the pipeline of new therapies remains inadequate, and preserving and advancing antimicrobial innovation has become a dire international priority. The congress devoted major attention not only to the spread of resistance but also to the policy and commercial failures preventing novel anti-infective therapies from reaching and remaining in clinical practice. Sulopenem and its optionality is exactly the type of innovation the world’s leading infectious-disease experts, policymakers, and AMR organizations are fighting for, right now. Mark it.
0 · Reply
DollerADay
DollerADay Aug. 7 at 4:42 AM
$ITRM Aug 31st is administrative, simply the end of the patient support copay program. Alto has been OOS after selling through the pipeline 4-6 weeks ago so it’s moot. If you want to see something interesting, check out the Pipeline tab. When Teneo took down the old information they mis-spelled “available.” Several reasons to specifically remove that page and that page alone, and the specific timing they did it. 😉
3 · Reply
Latest News on ITRM
No data available.
Steloco1
Steloco1 Aug. 9 at 1:09 PM
$ITRM Given the facts how this ludicrous loan was written, I'm hoping the court will only allow the original principal 51m.plus interest for RLN payment, of course hoping for far less. But Sarissa wants payment so where's the medium? Seems that would be a win for all to settle the RLN ordeal for a clean title. Since there's no royalty's on US sales and can't claim CIC this may be a compormidable bargaining solution.
1 · Reply
Amb8675309
Amb8675309 Aug. 9 at 7:15 AM
$ITRM I see they’re 25,000 watchers on this stock and there’s probably seven of us that regularly do anything so let me set the record straight- because I’ve blocked this guy that had zero followers and was following no one. We made a huge investment in this stock. The CEO misled me personally and I’m willing to testify to that. He spoke to other retail investors as well. People lost hundreds of thousands of dollars- the reason he could not sell when he received lowball offers is because he’s the one that entered into a terrible loan with Sarissa. He had a fiduciary duty to us, but he basically doomed himself. He made his asset unsellable except via liquidation . And because of that, I know people on here that lost huge chunks of their retirement account- hundreds of thousand of dollars- so if you don’t have anything to say, don’t question me as a larger shareholder- take your opinion and block me - I don’t want to hear it.
2 · Reply
Amb8675309
Amb8675309 Aug. 9 at 1:33 AM
$ITRM dead man walking- so talking to Us like he was serious about a launch- not cool
1 · Reply
Amb8675309
Amb8675309 Aug. 8 at 7:26 PM
$ITRM so when did CF know he was going to end up liquidating? As I said months ago, CF was a “dead man walking” the minute he received that 2021 CRL. To do another phase 3 would take 2 more years plus monthly cash burn plus new ph.3 trial costs/fees. CF agreed to terrible loan terms and omitted a CRL clause in the RLN master docs because of hubris and inexperience. I’m sure he realized this mistake THE DAY he received that CRL. By the time he gets approved in late 2024, CF knows he can’t actually fund a full 3 year launch. So here come lowballs- they’re low bec CF has no cash+unproven GTM thesis: of first office visit script should be Orly if patient chart warrants it, PLUS those pesky RLN holders have right to demand max. 414Mil. CF doesn’t “waste time” his actual answer to me of WTF did he do between 2024 low balls and an Aug 20/25 launch. He goes to PFE for 3yr extension- and PFE says, “sure” but no more non dilutive financing unless we approve it. CF knows proxy votes will fail…
1 · Reply
Adamantia
Adamantia Aug. 8 at 2:41 PM
$ITRM CROOKS I HOPE FISHMAN ROT'S IN A PLACE WORSE THAN HELL ,IN A BASEMENT SCREWED TO A WALL AND SLOWLY TAKING HIM ..... I'LL LEAVE THE REST TO THE FAMILY HERE THAT LOST ALL THEIR MONEY..
1 · Reply
DollerADay
DollerADay Aug. 8 at 3:52 AM
$ITRM For Teneo, a zero-equity outcome now risks looking catastrophic. Shareholders lost normal financial visibility during Orlynvah’s critical commercial inflection, and liquidation arrived just two business days before Q1 ended. Yet the filing described two counterparties discussing acquisition terms and a company that ran out of time and cash—not a failed drug or worthless asset. Teneo then presided over 5+ months of silence while DTC disappeared, massive trading continued, brokers removed positions, and shareholder custody records fractured. If this ends with a substantial sale and zero for equity, Teneo will have created an extraordinarily hostile factual record around that result. Bidder communications, valuations, RLN treatment, Pfizer economics and the entire waterfall become obvious targets for scrutiny. The custody disaster makes it worse: shareholders can reasonably ask why Teneo remained silent while ownership records deteriorated if equity supposedly never mattered.
2 · Reply
DollerADay
DollerADay Aug. 8 at 3:37 AM
$ITRM You can scroll through the history where I explained your next steps to this broker/custodian issue. This isn’t a new corporate action. What everyone here should be doing is “like” and repost the Tweets about this very issue under $ITRM. For Teneo to remain in absolute silence for going on 5 months in this custody disaster is indicative of one thing and one thing only.
2 · Reply
Hung25_25
Hung25_25 Aug. 8 at 2:03 AM
$ITRM it's my trun
0 · Reply
DollerADay
DollerADay Aug. 7 at 8:17 PM
$ITRM Here are the biggest AMR events of the year: ESCMID Global in April was the biggest major ID/AMR meeting already missed. * GAMRIC in September is the best remaining specialist AMR-development audience. * IDWeek in October is the strongest remaining U.S. clinical/commercial stage. * WAAW in November is the strongest global public-policy stage. ESCMID Global 2026 made one message unmistakable: antimicrobial resistance is accelerating, the pipeline of new therapies remains inadequate, and preserving and advancing antimicrobial innovation has become a dire international priority. The congress devoted major attention not only to the spread of resistance but also to the policy and commercial failures preventing novel anti-infective therapies from reaching and remaining in clinical practice. Sulopenem and its optionality is exactly the type of innovation the world’s leading infectious-disease experts, policymakers, and AMR organizations are fighting for, right now. Mark it.
0 · Reply
DollerADay
DollerADay Aug. 7 at 4:42 AM
$ITRM Aug 31st is administrative, simply the end of the patient support copay program. Alto has been OOS after selling through the pipeline 4-6 weeks ago so it’s moot. If you want to see something interesting, check out the Pipeline tab. When Teneo took down the old information they mis-spelled “available.” Several reasons to specifically remove that page and that page alone, and the specific timing they did it. 😉
3 · Reply
Aircastles
Aircastles Aug. 7 at 4:06 AM
$ITRM I need to get a life and instead of viewing uti websites at night need to frequent casinos or strip clubs like other normal folk do. Anyway, in lieu of nothing to work off of I do keep an eye on 8/31 as a date where something, anything, even small may happen. AI: “August 31 is worth watching because ORLYNVAH’s copay program is due to expire then, making it one of the few concrete near-term dates during the liquidation. If the program is extended, replaced, or its legal/manufacturer details change, that could provide a useful clue about whether the product is being maintained, transitioned, or wound down.” https://www.orlynvah.com/hcp/getting-started
3 · Reply
Toptopy
Toptopy Aug. 6 at 10:35 PM
$ITRM
1 · Reply
soulsearche
soulsearche Aug. 6 at 3:03 PM
$ITRM any news on the shareholder group formed for proxy, is the group active?
2 · Reply
ScottR89
ScottR89 Aug. 6 at 2:35 PM
$ITRM $ITRM At what point would Stocktwits remove this ticker thread?
1 · Reply
Brokensmoke
Brokensmoke Aug. 6 at 7:40 AM
$ITRM
0 · Reply
GatorMcKlusky
GatorMcKlusky Aug. 6 at 12:56 AM
$ITRM
0 · Reply
DollerADay
DollerADay Aug. 6 at 12:46 AM
$ITRM
0 · Reply
Ihavesunshineinmypocket
Ihavesunshineinmypocket Aug. 6 at 12:42 AM
$ITRM
1 · Reply
YakoCapital
YakoCapital Aug. 5 at 4:13 PM
$ITRM If I had a cristal ball: China → CR Gosun or Joincare Pharma Japan → Shionogi Middle East/LatAm → Menarini UK/Europe --> ADVANZ Pharma India/emerging markets → Orchid Australia/NZ → Link Medical Products S Korea --> Hanmi US --> Shionogi or Melinta or Innoviva
3 · Reply
Steloco1
Steloco1 Aug. 5 at 3:19 PM
$ITRM I was curious. Per chatgpt. As of today and based on the latest available information, no—ITRMF is not currently listed on the OTC Expert Market. It is trading on the OTC market, and current market data identifies it simply as an OTC security rather than an Expert Market-only security. �
2 · Reply
yoyo123456564
yoyo123456564 Aug. 5 at 12:25 PM
$ITRM Hi everyone, I understand that seeing the price at 0 rather than 0.0001 is disheartening. I’m frustrated by the situation too; however, I want to remind everyone that the price could even be 0.5 right now, but we have to keep in mind the notice Iterum published stating that transactions made from March 27th onwards are void as far as they are concerned. The only thing that matters is the price they manage to secure from the sale; my current average cost is 0.95 (from before March 27th). I realize the CEO ruined everything, but ultimately, I think we’ll manage to get at least $1 per share... call me a dreamer, but I can’t believe the drug and ten years of clinical trials aren't worth even $1 a share...
2 · Reply
buyitcheapest
buyitcheapest Aug. 5 at 11:47 AM
$ITRM She mentioned this. If you had been here for a millennium, things would have turned out better.
0 · Reply